Loading quotes...

Forecast

The analysts' average price target is €20.53 (+22.20%). The median is €17.45 (+3.87%).

Buy	24
Hold	15
Sell	0

News Go to news feed

Tandem Diabetes relies on pharmacy model, Mobi‑Patch and international direct sales for growth

Tandem Diabetes unveiled a long-term growth plan that includes a pharmacy-based pay-as-you-go model in the US, broader rollout of the tubeless Mobi‑Patch pump in the second half of 2026, and expansion of direct sales activities in selected international markets. The new US model is intended to remove the initial cost barrier for patients and bring up to 80% of US sales through pharmacies; internationally, the company expects higher prices and better follow-on care via direct business. New patient starts stalled in the second quarter, but Tandem expects growth in the second half of the year driven by product dynamics, seasonal demand and additional PBM coverage. At the same time, the company is advancing automation projects, including development toward a fully closed‑loop insulin system and integration of existing CGM technologies. » More on de.investing.com
Tandem Diabetes Care beats profit forecasts, shares fall after slight revenue miss

Tandem Diabetes Care reported adjusted EPS of -$0.31 for Q2, beating the analyst estimate of -$0.33, while revenue of $254.6 million missed estimates only slightly. Gross margin rose to 57% and adjusted EBITDA margin reached 3%, marking the fourth consecutive positive quarter. Management reaffirmed the full-year outlook, highlighted record shipments and progress in pharmacy distribution, and expects approval of Mobi Tubeless in the second half of 2026. The stock fell about 4.1% in regular trading and recovered slightly in after-hours trading. » More on de.investing.com
Tandem Diabetes Care lags after reimbursement shift clouds near-term revenue

Meridian Small Cap Growth Fund said Tandem Diabetes Care underperformed in Q2 as its transition to a pharmacy-based, pay-as-you-go reimbursement model reduced near-term revenue visibility and second-quarter guidance missed expectations. The fund noted added caution from a new competing patch-pump entrant and that Tandem’s lower-beta profile lagged in a market favoring high-beta names. Meridian remains invested, citing the company’s differentiated pump technology, growing installed base and recurring supply revenue, and views the reimbursement change as a long-term positive. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, Tandem Diabetes Care has already paid €1.14 in dividends. The last payout was in April 2023.

Financials

In the last quarter, Tandem Diabetes Care had revenue of €223.05m and net profit of -€18.55m

(EUR)	June 2026	YoY
Revenue	223.05m	9.23%
Gross profit	126.86m	18.81%
Net profit	-18.55m	58.28%
EBITDA	-12.04m	72.08%

Fundamentals

Metric	Value
Market capitalization	€1.18bn
Number of shares	69.58m
52-week high/low	€26.53 - €10.97
Dividends	No
Beta	1.66
P/E ratio	-20.35
PEG ratio	-0.19
P/B ratio	9.91
P/S ratio	1.26

Company profile

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Name	Tandem Diabetes Care
CEO	John F. Sheridan
Headquarters	San Diego, ca USA
Website	tandemdiabetes.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	14/11/2013
Employees	2,500